AGHEMO, Alessio Michele Goffredo
 Distribuzione geografica
Continente #
NA - Nord America 9.203
EU - Europa 1.599
AS - Asia 645
AF - Africa 290
OC - Oceania 12
SA - Sud America 8
Continente sconosciuto - Info sul continente non disponibili 7
Totale 11.764
Nazione #
US - Stati Uniti d'America 9.109
FI - Finlandia 431
IE - Irlanda 305
NG - Nigeria 270
SG - Singapore 253
CN - Cina 225
DE - Germania 163
IT - Italia 149
FR - Francia 148
NL - Olanda 101
CA - Canada 93
SE - Svezia 92
GB - Regno Unito 63
IL - Israele 42
RU - Federazione Russa 41
TR - Turchia 40
IN - India 38
BE - Belgio 34
EG - Egitto 16
MK - Macedonia 16
IR - Iran 14
HK - Hong Kong 10
AU - Australia 9
UA - Ucraina 9
PH - Filippine 8
RO - Romania 8
ES - Italia 7
A2 - ???statistics.table.value.countryCode.A2??? 6
GR - Grecia 6
CH - Svizzera 4
JP - Giappone 4
PL - Polonia 4
CL - Cile 3
ET - Etiopia 3
MD - Moldavia 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
PK - Pakistan 3
TW - Taiwan 3
AL - Albania 2
BD - Bangladesh 2
BG - Bulgaria 2
BR - Brasile 2
CZ - Repubblica Ceca 2
RS - Serbia 2
SA - Arabia Saudita 2
AT - Austria 1
BO - Bolivia 1
CO - Colombia 1
DK - Danimarca 1
EU - Europa 1
ID - Indonesia 1
IM - Isola di Man 1
IS - Islanda 1
PA - Panama 1
UG - Uganda 1
VE - Venezuela 1
Totale 11.764
Città #
Chandler 1.911
Wilmington 1.646
San Mateo 689
Ann Arbor 530
Helsinki 431
Boardman 371
Leawood 310
Dublin 303
New York 301
Lawrence 287
Princeton 287
Benin City 270
Ashburn 266
Shanghai 216
Singapore 192
Paris 148
Woodbridge 136
Fairfield 132
Amsterdam 100
Toronto 85
London 53
Milan 53
Seattle 53
San Diego 49
Kocaeli 39
Brussels 34
Norwalk 33
Falls Church 27
Moscow 27
Santa Clara 23
Pune 22
Phoenix 17
Cambridge 15
Los Angeles 15
Monmouth Junction 15
Frankfurt am Main 12
Rome 12
Asyut 11
Des Moines 11
Redmond 11
Redwood City 11
Andover 10
Clearwater 10
Falkenstein 8
Houston 8
Skopje 8
Hanover 7
Ardabil 6
Sacramento 6
Tappahannock 6
Bari 5
Bitola 5
Henderson 5
Abbiategrasso 4
Berlin 4
Winnipeg 4
Addis Ababa 3
Beijing 3
Chisinau 3
Dallas 3
Florence 3
Genoa 3
Gunzenhausen 3
Hangzhou 3
Olongapo City 3
Prilep 3
Taipei 3
Adliswil 2
Apo 2
Athens 2
Auckland 2
Aversa 2
Brno 2
Cairo 2
Cinisello Balsamo 2
Cusano Milanino 2
Edmonton 2
Gdansk 2
Kafr ash Shaykh 2
Kemerovo 2
Las Pinas 2
Las Vegas 2
Leipzig 2
Manila 2
Monza 2
Novokuznetsk 2
Penrith 2
Perth 2
Raleigh 2
Sale Marasino 2
St Petersburg 2
Torino 2
Venegono Superiore 2
Washington 2
Aachen 1
Al Mansurah 1
Alexandria 1
Augusta 1
Ballymena 1
Belgrade 1
Totale 9.343
Nome #
Outcome of Sars-COV-2-related thyrotoxicosis in survivors of Covid-19: a prospective study 120
12 weeks ombitasvir/paritaprevir-ritonavir plus ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis 84
A 13-day, interferon-free regimen for chronic hepatitis C genotype 1 patients: between fear and hope. 80
A Review of the Treatment of Chronic Hepatitis C Virus Infection in Cirrhosis 68
Daclatasvir : a team player rather than a prima donna in the treatment of hepatitis C 68
Real life experiences in HCV management in 2018 67
DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection 66
Lack of Correlation Between Serum Anti-HBcore Detectability and Hepatocellular Carcinoma in Patients With HCV-Related Cirrhosis 65
High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma 64
Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C 63
The prevalence, clinical features and response to antiviral therapy of patients with chronic hepatitis C who are seropositive for liver-kidney microsome type 1 antibodies 62
Assessing long-term treatment efficacy in chronic hepatitis B and C : Between evidence and common sense 62
Acute allograft rejection following interferon therapy for hepatitis C in recipients who have returned to dialysis after kidney transplant failure: Case study 61
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 61
Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population 60
Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response 60
Acute tubular necrosis following interferon-based therapy for hepatitis C : case study with literature review 60
Alpha-fetoprotein screening in patients with hepatitis C-induced cirrhosis who achieved a sustained virologic response in the direct-acting antiviral agents era 60
Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management 59
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naive patients with genotype 1 chronic hepatitis C 59
Age Might Confound the Impact of the Transmembrane 6 Superfamily Member 2 E167K Polymorphism on Hepatic Fibrosis in Hepatitis C Virus-Infected Patients REPLY 58
Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside 58
The role of hepatic venous pressure gradient in hepatitis C virus compensated cirrhosis 58
REGULATION OF VASOPRESSIN SECRETION AFTER ADMINISTRATION OF SODIUM-NITROPRUSSIDE IN HYPERTENSIVES 58
Genomewide Association Study of Severe Covid-19 with Respiratory Failure 58
High mortality in COVID-19 patients with mild respiratory disease 58
Early detection of elevated cardiac biomarkers to optimise risk stratification in patients with COVID-19 58
Quantification of Core Antigen Monitors Efficacy of Direct-acting Antiviral Agents in Patients With Chronic Hepatitis C Virus Infection 57
Sofosbuvir Treatment in the Pre and Post Liver Transplantation Phase: The Sooner, the Better 57
The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent 57
Hepatitis C treatment in patients with kidney disease 57
Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: A pooled analysis of clinical trials 57
Anemia during peginterferon-ribavirin therapy results from both increased suppression of erythroid differentiation and haemolysis 57
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure 57
Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: Effects on blood pressure control and mortality 57
Estimating HCV disease burden - volume 3 (editorial) 56
Sofosbuvir for the treatment of chronic hepatitis C : between current evidence and future perspectives 56
EASL Recommendations on Treatment of Hepatitis C 2014 56
Hepatorenal Syndrome and Novel Advances in its Management 56
The clinical impact of a 24-week treatment course of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia 56
COINCIDENCE OF CALCITONIN-GENE-RELATED PEPTIDE IMMUNOREACTIVITY AND TERMINAL FIELDS OF EFFERENTS FROM THE CARDIOVASCULAR PORTION OF THE FASTIGIAL NUCLEUS - PRELIMINARY-REPORT 56
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 56
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65years with HCV genotype 1 cirrhosis 56
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission 56
Pegylated IFN-alpha 2a and ribavirin in the treatment of hepatitis C 55
Is a 24 week treatment schedule with PegInterferon and Ribavirin too short for HCV genotype 3 cirrhotics? 55
No clinical impact of HCV RNA determination at the end of treatment in patients receiving directly acting antivirals 55
OSMOREGULATION OF VASOPRESSIN DURING ACUTE LOWERING OF ARTERIAL-PRESSURE BY CLONIDINE IN MODERATE HYPERTENSION 55
Lack of rapid virological response. predicts interferon-alpha 2b/ribavirin therapy failure in HCV genotype 2 patients: a single-centre study 55
Chronic hepatitis C: standard of care and perspective 54
Optimizing treatment with pegylated interferon-ribavirin of genotype 3 chronic hepatitis C : more questions than answers 54
Will the benefits of treatment for chronic hepatitis C be retained in the interferon-free era? 54
Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection 54
Triple therapy with first-generation Protease Inhibitors for patients with genotype 1 chronic hepatitis C: Recommendations of the Italian Association for the Study of the Liver (AISF) 54
A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis 53
Hepatitis C virus genotypes and patterns of peginterferon alfa-2b/ribavirin treatment failure in patients with cirrhosis : a single center study of 471 naïve patients 53
From current status to optimization of HCV treatment: Recommendations from an expert panel 53
All That Glitters is Not Gold in Vedolizumab Therapy for Patients With Inflammatory Bowel Diseases and Primary Sclerosing Cholangitis 53
Interferon in the treatment of chronic hepatitis C: a drug caught between past and future 52
Peginterferon maintenance therapy in patients with advanced hepatitis C to prevent hepatocellular carcinoma: The plot thickens 52
Therapy expectations and physical comorbidity affect quality of life in chronic hepatitis C virus infection 52
Increased risk of hepatocellular carcinoma in HCV (+) non responder cirrhotics with high liver cell proliferation 52
Prevalence and clinical significance of intrahepatic cholangiocellular carcinoma with radiological enhancement pattern mimicking hepatocellular carcinoma 52
Interferon-free oral therapy for hepatitis C : "faraway, so close!" 51
A rapid point-of-care test for the diagnosis of HCV infection: tipping the balance to screening extension beyond high risk populations? 51
Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failure 51
Hyporesponsiveness to PegIFNα2B plus ribavirin in patients with hepatitis C-related advanced fibrosis 51
Allelic inhibition of displacement activity: A simplified one tube allele-specific PCR for evaluation of ITPA polymorphisms 51
Prevalence and Clinical Impact of Hepatitis E Virus in Immunosuppressed Patient after Liver Transplantation 51
HCV genotype 3: An independent predictor of fibrosis progression in chronic hepatitis C 50
The Role Of Serum Alphafetoprotein Determination In HCV-Cirrhosis After Antiviral Treatment 50
Treatment of chronic hepatitis C: can complexity pave the way towards elimination? 50
Treatment of experienced and naïve patients with hepatitis C: focus on telaprevir. 50
Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection 50
Interferon lambda 3 rs12979860 polymorphism in patients with haemophilia and HCV infection: a predictor of spontaneous viral clearance and sustained virological response 50
Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, metabolic syndrome and hepatocellular carcinoma-a composite scenario 49
JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1 49
Safety of vedolizumab in liver transplant recipients: A systematic review 49
Chemokine Receptor 5 Has No Major Role in the Severity of Hepatitis C Virus-Related Liver Damage 48
Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy 48
Role of liver biopsy in hepatocellular carcinoma 48
Diagnosis of hepatocellular carcinoma in cirrhosis by dynamic contrast imaging: The importance of tumor cell differentiation 47
Mediterranean diet and NAFLD: what we know and questions that still need to be answered. 47
Reply to: "The "pegylated" story continues - Perhaps because both ends (alpha 2a and alpha 2b) are true?" 47
Daclatasvir for the treatment of chronic hepatitis C 47
De novo membrano-proliferative nephritis following interferon therapy for chronic hepatitis c (case study and literature review) 47
Interferon-ribavirin therapy induces serum antibodies determining 'rods and rings' pattern in hepatitis C patients 47
Deciding on interferon-free treatment for chronic hepatitis C : Updating liver stiffness cut-off values to maximize benefit 47
Autoimmune Hepatitis During Ledipasvir/Sofosbuvir Treatment of Hepatitis C: A Case Report 47
Impaired response to interferon-alpha 2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection 46
Low risk of hepatitis B reactivatioin in patients with chronic hepatitis C and concurrent inactive hepatitis B infection treated with interferon and ribavirin 46
The natural history of portal hypertension in patients with HCV related compensated cirrhosis undergoing interferon ribavirin therapy 46
Post-liver transplantation graft biopsies should not be used to assess the IL28B donor genotype in HCV recipients 46
Bridging all oral DAA therapy from wait time to post-liver transplant to improve HCV eradication? 46
The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy 45
Interaction between PNPLA3 I148M variant and age at infection in determining fibrosis progression in chronic hepatitis C 45
Commentary : Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C 45
Global characterization of tumor infiltrate of Intrahepatic Cholangiocarcinoma by single cell sequencing 45
Recovery after L-DOPA treatment in peg-interferon and ribavirin induced parkinsonism 45
Second wave anti-HCV protease inhibitors: too little too late? 44
Totale 5.504
Categoria #
all - tutte 85.127
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 85.127


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202011 0 0 0 0 0 0 0 0 0 0 0 11
2020/20213.072 22 30 27 16 8 964 481 213 528 399 13 371
2021/20221.690 79 18 59 359 20 21 77 221 121 197 405 113
2022/20234.725 673 210 456 559 429 407 7 414 873 361 271 65
2023/20242.452 179 260 545 127 102 414 144 153 37 46 248 197
Totale 11.950